3 Drug Launches You Need to Know in 2013: Pfizer, NPS Pharma, Ariad The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for investors ...

Eli Lilly & Co. (NYSE:LLY) told the Wall Street Journal that it doesn't believe the liver toxicity has to do with the mechanism of inhibiting BACE and is most likely an off-target effect.

Merck & Co., Inc (NYSE:MRK) is axing jobs and also eliminating an entire peel of senior management from its R&D arm.

Merck & Co., Inc. (NYSE:MRK) has maintained a steady path higher during the last 12 months, having climbed more than 14% year-to-date, and about 23% on a year-over-year basis.

In what is becoming a trend, options trading on Merck & Co., Inc. (NYSE:MRK) is heavy today, with 60,000 contracts changing hands -- nearly 90% ahead of the norm.

Merck & Co. is cutting jobs and stripping a layer of senior management from its research-and-development arm, as its new chief seeks to turnaround a unit he said is marked by "the complexity of our organizational design.

Merck & Company, Inc. ( MRK ) will begin trading ex-dividend on June 13, 2013. A cash dividend payment of $0.43 per share is scheduled to be paid on July 08, 2013.

Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co.

Merck & Co., Inc. (NYSE:MRK) was in 56 hedge funds' portfolio at the end of March. MRK investors should pay attention to a decrease in hedge fund sentiment of late.

Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) recently announced plans to mount a massive $15 billion share buyback program that would result in the cancellation of up to 10 percent of its total share float.